Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pearl Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01085045
First received: March 9, 2010
Last updated: September 11, 2012
Last verified: September 2012
  Purpose

The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the combination to its components, and to assess the relative contribution of the components compared with placebo, in patients with moderate to very severe COPD.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: PT003 MDI
Drug: PT005 MDI
Drug: Placebo MDI
Drug: Tiotropium bromide 18 μg (Spiriva Handihaler®)
Drug: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Drug: PT001 MDI
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (7 Days), Four-Period, Eight-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Two Doses of PT003, Two Doses of PT005 and One Dose of PT001 in Patients With Moderate to Very Severe COPD, Compared With Foradil® Aerolizer® (12 μg, Open-Label) and Spiriva® Handihaler® (18 μg, Open-Label) as Active Controls

Resource links provided by NLM:


Further study details as provided by Pearl Therapeutics, Inc.:

Primary Outcome Measures:
  • Change in forced expiratory volume in one second (FEV1) area under the curve from 0 to 12 hours [AUC(0-12)] from test day baseline [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
    Day 7 time points for FEV1 are measured over 12 hours


Secondary Outcome Measures:
  • Peak FEV1, time to onset of action (greater than or equal to 10% improvement in mean FEV1), proportion of patients with greater than or equal to 12% improvement in FEV1 and peak improvement in inspiratory capacity (IC) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Day 1 timepoints for FEV1 and IC are measured over 2 hours

  • Improvement in pre-dose FEV1, peak FEV1, peak improvement in IC, and trough FEV1 [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
    Day 7 time points for FEV1 are measured over 12 hours

  • Mean daily peak expiratory flow rate [ Time Frame: Day 1 through Day 7 ] [ Designated as safety issue: No ]

Enrollment: 118
Study Start Date: March 2010
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Inhaled PT003 (Dose 1)
PT003 MDI Dose 1
Drug: PT003 MDI
Inhaled PT003 MDI administered as two puffs BID for 7 days
Experimental: Inhaled PT003 (Dose 2)
PT003 MDI Dose 2
Drug: PT003 MDI
Inhaled PT003 MDI administered as two puffs BID for 7 days
Experimental: Inhaled PT005 (Dose 1)
PT005 MDI Dose 1
Drug: PT005 MDI
Inhaled PT005 MDI administered as two puffs BID for 7 days
Experimental: Inhaled PT005 (Dose 2)
PT005 MDI Dose 2
Drug: PT005 MDI
Inhaled PT005 MDI administered as two puffs BID for 7 days
Placebo Comparator: Inhaled Placebo
Placebo MDI
Drug: Placebo MDI
Inhaled placebo administered as two puffs BID for 7 days
Active Comparator: Tiotropium bromide 18 μg (Spiriva Handihaler®)
Tiotropium Bromide inhalation powder
Drug: Tiotropium bromide 18 μg (Spiriva Handihaler®)
Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
Active Comparator: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Formoterol fumarate inhalation powder 12 μg
Drug: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
Experimental: Inhaled PT001 (Dose 1)
PT001 MDI Dose 1
Drug: PT001 MDI
Inhaled PT001 MDI administered as two puffs BID for 7 days

  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent
  • 40 - 80 years of age
  • Clinical history of COPD with airflow limitation that is not fully reversible
  • Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods
  • Current/former smokers with at least a 10 pack-year history of cigarette smoking
  • A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70
  • A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of predicted normal values
  • Able to change COPD treatment as required by protocol

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Primary diagnosis of asthma
  • Alpha-1 antitrypsin deficiency as the cause of COPD
  • Active pulmonary diseases
  • Prior lung volume reduction surgery
  • Abnormal chest X-ray (or CT scan) not due to the presence of COPD
  • Hospitalized due to poorly controlled COPD within 3 months of Screening
  • Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)
  • Cancer that has not been in complete remission for at least 5 years
  • Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives

Other protocol defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01085045

Locations
United States, Florida
Clinical Research of West Florida, Inc.
Clearwater, Florida, United States, 33765
United States, North Carolina
American Health Research
Charlotte, North Carolina, United States, 28207
United States, Oregon
Clinical Research Institute of Southern Oregon, PC
Medford, Oregon, United States, 97504
United States, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina, United States, 29303
Australia, New South Wales
Austrials
Caringbah, New South Wales, Australia, 2229
Woolcock
Glebe, New South Wales, Australia, 2037
Austrials
Hornsby, New South Wales, Australia, 2077
Australia, Queensland
Austrials
Auchenflower, Queensland, Australia, 4066
Q-Pharm
Herston, Queensland, Australia, 4006
Australia, South Australia
Respiratory Research Foundation - Burnside War Memorial Hospital
Adelaide, South Australia, Australia
Australia, Victoria
Monash Medical Centre
Clayton, Victoria, Australia, 3168
Australia, Western Australia
Lung Institute of WA
Nedlands, Western Australia, Australia, 6006
New Zealand
Greenlane Clinical Centre
Epsom, Auckland, New Zealand, 1051
NZ Respiratory & Sleep Institute
Greenlane East, Auckland, New Zealand, 1051
Waikato Hospital
Hamilton, Waikato, New Zealand, 3240
P3 Research
Crofton Downs, Wellington, New Zealand, 6143
Sponsors and Collaborators
Pearl Therapeutics, Inc.
Investigators
Study Director: Colin Reisner, M.D. Pearl Therapeutics, Inc.
  More Information

No publications provided

Responsible Party: Pearl Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01085045     History of Changes
Other Study ID Numbers: PT0031002
Study First Received: March 9, 2010
Last Updated: September 11, 2012
Health Authority: United States: Food and Drug Administration
Australia: Human Research Ethics Committee
New Zealand: Standing Committee on Therapeutic Trials (SCOTT) Committee
New Zealand: Medsafe

Keywords provided by Pearl Therapeutics, Inc.:
COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Bromides
Formoterol
Tiotropium
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Anti-Asthmatic Agents
Anticonvulsants
Autonomic Agents
Bronchodilator Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014